^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HS-10376

    i
    Other names: HS-10376
    Associations

    News

    Trials
    Company:
    Jiangsu Hansoh Pharma
    Drug class:
    HER2 exon 20 mutation inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=380, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1/2 trial • HER2 exon 20
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation
    |
    HS-10376